These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Sympathetic skin response in scleroderma. Raszewa M; Hausmanowa-Petrusewicz I; Błaszczyk M; Jabłońska S Electromyogr Clin Neurophysiol; 1991 Dec; 31(8):467-72. PubMed ID: 1797542 [TBL] [Abstract][Full Text] [Related]
47. [Systemic sclerosis--clinical course and treatment possibilities]. Szymańska E; Maj M; Rudnicka L Przegl Lek; 2005; 62(12):1538-41. PubMed ID: 16786791 [TBL] [Abstract][Full Text] [Related]
48. Associations of right ventricular myocardial function with skin and pulmonary involvement in asymptomatic patients with systemic sclerosis. D'Andrea A; Bellissimo S; Scotto di Uccio F; Vigorito F; Moscato F; Tozzi N; Di Donato M; Citro R; Stisi S; Scherillo M Ital Heart J; 2004 Nov; 5(11):831-9. PubMed ID: 15633438 [TBL] [Abstract][Full Text] [Related]
49. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM; Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489 [TBL] [Abstract][Full Text] [Related]
53. Progressive systemic sclerosis and nervous system involvement. A review of 14 cases. Dierckx RA; Aichner F; Gerstenbrand F; Fritsch P Eur Neurol; 1987; 26(3):134-40. PubMed ID: 3032642 [TBL] [Abstract][Full Text] [Related]
54. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. Nevskaya T; Baron M; Pope JE; Rheumatology (Oxford); 2017 Jul; 56(7):1111-1122. PubMed ID: 28340090 [TBL] [Abstract][Full Text] [Related]
55. 2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. Alhajeri H; Hudson M; Fritzler M; Pope J; Tatibouet S; Markland J; Robinson D; Jones N; Khalidi N; Docherty P; Kaminska E; Masetto A; Sutton E; Mathieu JP; Ligier S; Grodzicky T; LeClercq S; Thorne C; Gyger G; Smith D; Fortin PR; Larché M; Baron M Arthritis Care Res (Hoboken); 2015 Apr; 67(4):582-7. PubMed ID: 25233870 [TBL] [Abstract][Full Text] [Related]
56. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. Hulshof MM; Bouwes Bavinck JN; Bergman W; Masclee AA; Heickendorff L; Breedveld FC; Dijkmans BA J Am Acad Dermatol; 2000 Dec; 43(6):1017-23. PubMed ID: 11100017 [TBL] [Abstract][Full Text] [Related]
57. Diagnosis and treatment of scleroderma. Adnan ZA Acta Med Indones; 2008 Apr; 40(2):109-12. PubMed ID: 18560030 [TBL] [Abstract][Full Text] [Related]
58. [Abnormal electroencephalography results and specific language impairment: towards a theoretical neurodevelopmental model?]. Lévy-Rueff M; Bourgeois M; Assous A; Beauquier-Maccota B; Boucheron E; Clouard C; Dondé S; Fostini O; Pinot P; Mosser A; Rittori G; Soufflet C; Vaivre-Douret L; Golse B; Robel L Encephale; 2012 Sep; 38(4):318-28. PubMed ID: 22980473 [TBL] [Abstract][Full Text] [Related]
59. [Symptoms from the internal organs of patients with systemic sclerosis in the light of selected diagnostic tests]. Sierakowska M; Sierakowski S; Doroszkiewicz H; Lewko J; Jankowiak B; Kowalczuk K; Van Damme-Ostapowicz K; Krajewska-Kułak E Pol Merkur Lekarski; 2011 Feb; 30(176):116-20. PubMed ID: 21544981 [TBL] [Abstract][Full Text] [Related]
60. Clinical, socio-demographic, neurophysiological and neuropsychiatric evaluation of children with volatile substance addiction. Uzun N; Kendirli Y Child Care Health Dev; 2005 Jul; 31(4):425-32. PubMed ID: 15948879 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]